Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors

British Journal of Cancer

Volumn 112, Issue 6, 2015, Pages 1011-1016

  Kloth, J S L ^a   Pagani, A ^b   Verboom, M C ^c   Malovini, A ^d   Napolitano, C ^b   Kruit, W H J ^a   Sleijfer, S ^a,e   Steeghs, N ^f   Zambelli, A ^g   Mathijssen, R H J ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b IRCCS   (Italy)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Salvatore Maugeri Research and Care Institute   (Italy)

^e Cancer Genomics Center Netherlands   (Netherlands)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

^g PAPA GIOVANNI XXIII HOSPITAL   (Italy)

Author keywords

arrhythmia; ECG; QTc interval; tyrosine kinase inhibitors

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VEMURAFENIB; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; DRUG EFFECT; ELECTROCARDIOGRAPHY MONITORING; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPOKALEMIA; ITALY; KIDNEY CANCER; LIVER CELL CARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; NETHERLANDS; PRIORITY JOURNAL; QT PROLONGATION; QTC INTERVAL; RETROSPECTIVE STUDY; ANTAGONISTS AND INHIBITORS; ARRHYTHMIAS, CARDIAC; CHEMICALLY INDUCED; CLINICAL TRIAL; ELECTROCARDIOGRAPHY; ENZYMOLOGY; INCIDENCE; JERVELL-LANGE NIELSEN SYNDROME; MIDDLE AGED; PROCEDURES; RISK;

AGED; ARRHYTHMIAS, CARDIAC; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INCIDENCE; ITALY; JERVELL-LANGE NIELSEN SYNDROME; MALE; MIDDLE AGED; NETHERLANDS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RETROSPECTIVE STUDIES; RISK;

EID: 84925307065     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.82     Document Type: Article

References (24)

1. Bello CL, Mulay M, Huang X, Patyna S, Dinolfo M, Levine S, Van Vugt A, Toh M, Baum C, Rosen L (2009) Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokineticpharmacodynamic evaluation of sunitinib. Clin Cancer Res 15: 7045-7052.
2. Benoit SR, Mendelsohn AB, Nourjah P, Staffa JA, Graham DJ (2005) Risk factors for prolonged QTc among US adults: Third National Health and Nutrition Examination Survey. Eur J Cardiovasc Prev Rehabil 12: 363-368.
3. Committee for Proprietary Medicinal Products (CPMP). Points to consider: The Assessment of the Potential for QT Interval Prolongation by non- Cardiovascular Medicinal Products, Vol. 1997. The European Agency for the Evaluation of Medicinal Products: London, UK.
4. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. U.S. Department of Health and Human Services; National Institutes of Health, National Cancer Institute, published 14 June 2010.
5. Curigliano G, Spitaleri G, Fingert HJ, de Braud F, Sessa C, Loh E, Cipolla C, De Pas T, Goldhirsch A, Shah R (2008) Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development. Eur J Cancer 44: 494-500.
6. de Jonge M, Verweij J (2008) QTc prolongation and/or oncology drug development: whos in danger? Eur J Cancer 44: 486-487.
7. Dogan E, Yorgun H, Petekkaya I, Ozer N, Altundag K, Ozisik Y (2012) Evaluation of cardiac safety of lapatinib therapy for ErbB2-positive metastatic breast cancer: a single center experience. Med Oncol 29: 3232-3239.
8. Doherty KR, Wappel RL, Talbert DR, Trusk PB, Moran DM, Kramer JW, Brown AM, Shell SA, Bacus S (2013) Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol 272: 245-255.
9. Dong Q, Fu XX, Du LL, Zhao N, Xia CK, Yu KW, Cheng LX, Du YM (2013) Blocking of the human ether-a-go-go-related gene channel by imatinib mesylate. Biol Pharm Bull 36: 268-275.
10. El-Sherif N, Turitto G (2003) Torsade de pointes. Curr Opin Cardiol 18: 6-13.
11. Grant AO (2009) Cardiac ion channels. Circ Arrhythm Electrophysiol 2: 185-194.
12. Heath EI, Infante J, Lewis LD, Luu T, Stephenson J, Tan AR, Kasubhai S, LoRusso P, Ma B, Suttle AB, Kleha JF, Ball HA, Dar MM (2013) A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors. Cancer Chemother Pharmacol 71: 565-573.
13. Kobza R, Roos M, Niggli B, Abacherli R, Lupi GA, Frey F, Schmid JJ, Erne P (2009) Prevalence of long and short QT in a young population of 41,767 predominantly male Swiss conscripts. Heart Rhythm 6: 652-657.
14. Lee HA, Kim EJ, Hyun SA, Park SG, Kim KS (2010) Electrophysiological effects of the anti-cancer drug lapatinib on cardiac repolarization. Basic Clin Pharmacol Toxicol 107: 614-618.
15. Li EC, Esterly JS, Pohl S, Scott SD, McBride BF (2010) Drug-induced QT-interval prolongation: considerations for clinicians. Pharmacotherapy 30: 684-701.
16. Molnar J, Zhang F, Weiss J, Ehlert FA, Rosenthal JE (1996) Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events. J Am Coll Cardiol 27: 76-83.
17. Moss AJ (2003) Long QT Syndrome. JAMA 289: 2041-2044.
18. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369: 722-731.
19. Sagie A, Larson MG, Goldberg RJ, Bengtson JR, Levy D (1992) An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol 70: 797-801.
20. Shah RR, Morganroth J, Shah DR (2013) Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf 36: 295-316.
21. Strevel EL, Ing DJ, Siu LL (2007) Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 25: 3362-3371.
22. Tolcher AW, Appleman LJ, Shapiro GI, Mita AC, Cihon F, Mazzu A, Sundaresan PR (2011) A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol 67: 751-764.
23. Trinkley KE, Page 2nd RL, Lien H, Yamanouye K, Tisdale JE (2013) QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Curr Med Res Opin 29: 1719-1726.
24. Yetkin E, Senen K, Ileri M, Atak R, Topaloglu S, Ergun K, Yanik A, Tandogan I, Cehreli S, Duru E, Demirkan D (2001) Diurnal variation of QT dispersion in patients with and without coronary artery disease. Angiology 52: 311-316.